Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc Issues FY 2013 Guidance Below Analysts' Estimates


Thursday, 7 Mar 2013 07:00am EST 

Sarepta Therapeutics Inc announced that for fiscal 2013, it expects revenue to be in the range of $18 to $24 million and that loss from operations to be in the $85 to $115 million range. The revenue guidance is based on the assumption that Sarepta will continue to receive funding from its current government contracts for Marburg. If Sarepta does not continue to receive this funding, its revenue guidance would change significantly. Additionally, the operating loss guidance is largely based on continuing development and scale up manufacturing for eteplirsen and our follow-on DMD drugs. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $31 million and net income of $(45) million for fiscal 2013. 

Company Quote

24.4
0.17 +0.70%
17 Apr 2014